Prostate cancer prevention trials in the USA

European Journal of Cancer

Volumn 36, Issue 10, 2000, Pages 1312-1315

  Brawley, O W ^a   Parnes, H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

5 alpha reductase inhibitor; Alpha tocopherol; Chemoprevention; Clinical trials; Prostate; Prostate cancer; Selenium

Indexed keywords

ALPHA TOCOPHEROL; ENZYME INHIBITOR; FINASTERIDE; SELENIUM; STEROID 5ALPHA REDUCTASE;

AGED; ANIMAL; CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; MALE; MIDDLE AGED; PROSTATE TUMOR; RABBIT; REVIEW; RISK FACTOR;

AGED; ANIMALS; CLINICAL TRIALS; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RABBITS; RISK FACTORS; SELENIUM; TESTOSTERONE 5-ALPHA-REDUCTASE; VITAMIN E;

EID: 0034199463     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00105-2     Document Type: Article

References (32)

1. Chan JM, Stampfer MJ, Giovannucci EL, et al. What causes prostate cancer A brief summary of the epidemiology? Semin Cancer Biol 1998, 8, 263-273.
2. Giovannucci E, Clinton SK. Tomatoes, lycopene, and prostate cancer. Proc Soc Exp Biol Med 1998, 218, 129-139.
3. Giovannucci E. Selenium and risk of prostate cancer. Lancet 1998, 352, 755-756.
4. Greenwald P, Kelloff G, Burch-Whitman C, Kramer BS. Chemoprevention. CA Cancer J Clin 1995, 45, 31-49.
5. Redman C, Scott JA, Baines AT, et al. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett 1998, 125, 103-110.
6. Hong WK, Lippman SM. Cancer chemoprevention. J Natl Cancer Inst Monogr 1995, 49-53.
7. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 1994, 12, 851-873.
8. Ma J, Stampfer MJ, Gann PH, et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 1998, 7, 385-390.
9. Thompson IM, Coltman CAJ, Crowley J. Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. Prostate 1997, 33, 217-221.
10. Coltman CAJ, Thompson IMJ, Feigl P. Prostate Cancer Prevention Trial (PCPT) update. Eur Urol 1999, 35, 544-547.
11. Brawley OW, Ford LG, Thompson I, Perlman JA, Kramer BS. 5-Alpha-reductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev 1994, 3, 177-182.
12. Trachtenberg J. Healthcare resources should be targeted to chemoprevention: the argument against. Eur Urol 1996, 29(Suppl. 2), 17-18.
13. Bologna M, Muzi P, Biordi L, Festuccia C, Vicentini C. Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology 1995, 45, 282-290.
14. Delos S, lehle C, Martin PM, Raynaud JP. Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol 1994, 48, 347-352.
15. Tsukamoto S, Akaza H, Imada S, et al. Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex. J Natl Cancer Inst 1995, 87, 842-843.
16. Roehrborn CG, Boyle P, Bergner D, et al. Serum prostatespecific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999, 54, 662-669.
17. Zaccheo T, Giudici D, di Salle E. Effect of turosteride, a 5 alphareductase inhibitor, on the Dunning R3327 rat prostatic carcinoma. Prostate 1997, 30, 85-91.
18. Homma Y, Kaneko M, Kondo Y, Kawabe K, Kakizoe T. Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143. J Natl Cancer Inst 1997, 89, 803-807.
19. Zaccheo T, Giudici D, di Salle E. Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats. Prostate 1998, 35, 237-242.
20. Geller J. Clinical review: 67: approach to chemoprevention of prostate cancer. J Clin Endocrinol Metab 1995, 80, 717-719.
21. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994, 43, 284-292.
22. Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 1996, 155, 1251-1259.
23. Ekman P. Finasteride in the treatment of benign prostatic hypertrophy: an update. New indications for finasteride therapy. ScandJ Urol Nephrol 1999, 203(Suppl.), 15-20.
24. Gormley GJ. Finasteride: a clinical review. Biomed Pharmacother 1995, 49, 319-324.
25. Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: review of available data. J Urol 1996, 155, 3-9.
26. Feigl P, Blumenstein B, Thompson I, et al. Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 1995, 16, 150-163.
27. Oesterling JE, Roy J, Agha A, et al. Biologic variability of prostatespecific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group. Urology 1997, 50, 13-18.
28. Coltman CAJ, Thompson IMJ, Feigl P. Prostate Cancer Prevention Trial (PCPT) update. Eur Urol 1999, 35, 544-547.
29. Thompson IM, Coltman CAJ, Crowley J. Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. Prostate 1997, 33, 217-221.
30. Clark LC, Dalkin B, Krongrad A, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a doubleblind cancer prevention trial. Br J Urol 1998, 81, 730-734.
31. Albanes D, Heinonen OP, Taylor PR, et al. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996, 88, 1560-1570.
32. Anonymous. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann Epidemiol 1994, 4, 1-10.